eXoZymes (NASDAQ:EXOZ) Stock Price Up 2.4% – Here’s Why

eXoZymes Inc. (NASDAQ:EXOZ)’s stock price rose 2.4% on Monday . The company traded as high as $7.38 and last traded at $7.38. Approximately 1,167 shares traded hands during mid-day trading, a decline of 63% from the average daily volume of 3,177 shares. The stock had previously closed at $7.21.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of eXoZymes in a report on Monday, December 29th. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, eXoZymes presently has a consensus rating of “Sell”.

eXoZymes Stock Down 0.7%

The company has a market cap of $60.48 million, a P/E ratio of -9.35 and a beta of 2.52. The company has a quick ratio of 4.53, a current ratio of 4.53 and a debt-to-equity ratio of 0.01. The company has a fifty day moving average of $9.25 and a 200 day moving average of $11.92.

eXoZymes Company Profile

eXoZymes, Inc develops, manufactures and supplies a range of enzymes and reagents designed for molecular biology research and diagnostic applications. The company’s enzyme engineering platform underpins a portfolio of products aimed at supporting nucleic acid purification, amplification and analysis workflows.

Key offerings from eXoZymes include magnetic bead–based nucleic acid extraction kits, DNA polymerases, reverse transcriptases, proteases and custom enzyme services. In addition, the company provides molecular diagnostic test kits designed for pathogen detection, leveraging scalable production processes and quality systems aligned with regulatory standards.

eXoZymes serves academic research institutions, biotechnology and pharmaceutical companies, and clinical diagnostic laboratories worldwide.